{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:00:14Z","timestamp":1790744414888,"version":"4.1.0"},"reference-count":102,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The classic description of diabetic kidney disease (DKD) involves progressive stages of glomerular hyperfiltration, microalbuminuria, proteinuria, and a decline in the estimated glomerular filtration rate (eGFR), leading to dialysis. In recent years, this concept has been increasingly challenged as evidence suggests that DKD presents more heterogeneously. Large studies have revealed that eGFR decline may also occur independently from the development of albuminuria. This concept led to the identification of a new DKD phenotype: non-albuminuric DKD (eGFR &lt; 60 mL\/min\/1.73 m2, absence of albuminuria), whose pathogenesis is still unknown. However, various hypotheses have been formulated, the most likely of which is the acute kidney injury-to-chronic kidney disease (CKD) transition, with prevalent tubular, rather than glomerular, damage (typically described in albuminuric DKD). Moreover, it is still debated which phenotype is associated with a higher cardiovascular risk, due to contrasting results available in the literature. Finally, much evidence has accumulated on the various classes of drugs with beneficial effects on DKD; however, there is a lack of studies analyzing the different effects of drugs on the various phenotypes of DKD. For this reason, there are still no specific guidelines for therapy in one phenotype rather than the other, generically referring to diabetic patients with CKD.<\/jats:p>","DOI":"10.3390\/biom13050752","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T02:50:00Z","timestamp":1682563800000},"page":"752","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9061-0368","authenticated-orcid":false,"given":"Sabrina","family":"Scilletta","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9021-6101","authenticated-orcid":false,"given":"Maurizio","family":"Di Marco","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0429-9807","authenticated-orcid":false,"given":"Nicoletta","family":"Miano","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6593-8823","authenticated-orcid":false,"given":"Agnese","family":"Filippello","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-8279","authenticated-orcid":false,"given":"Stefania","family":"Di Mauro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-3365","authenticated-orcid":false,"given":"Alessandra","family":"Scamporrino","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Musmeci","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Coppolino","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Giacomo Barbagallo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6036-927X","authenticated-orcid":false,"given":"Giosiana","family":"Bosco","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-3649","authenticated-orcid":false,"given":"Roberto","family":"Scicali","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1781-0902","authenticated-orcid":false,"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Purrello","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Pino","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Roelofs, J.J., and Vogt, L. (2019). Diabetic Nephropathy: Pathophysiology and Clinical Aspects, Springer.","DOI":"10.1007\/978-3-319-93521-8"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in Diabetes-Related Complications in the United States, 1990\u20132010","volume":"370","author":"Gregg","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in Albuminuria and Subsequent Risk of End-Stage Kidney Disease: An Individual Participant-Level Consortium Meta-Analysis of Observational Studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.numecd.2021.08.030","article-title":"High Glomerular Filtration Rate Is Associated with Impaired Arterial Stiffness and Subendocardial Viability Ratio in Prediabetic Subjects","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2215\/CJN.11111016","article-title":"Diagnosis and Management of Type 2 Diabetic Kidney Disease","volume":"12","author":"Doshi","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","article-title":"Renal Insufficiency in the Absence of Albuminuria and Retinopathy Among Adults with Type 2 Diabetes Mellitus","volume":"289","author":"Kramer","year":"2003","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2337\/dc08-2186","article-title":"Nonalbuminuric Renal Impairment in Type 2 Diabetic Patients and in the General Population (National Evaluation of the Frequency of Renal Impairment CO-Existing with NIDDM [NEFRON] 11)","volume":"32","author":"Thomas","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"871272","DOI":"10.3389\/fendo.2022.871272","article-title":"Comparison of Nonalbuminuric and Albuminuric Diabetic Kidney Disease Among Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/ndt\/gfh470","article-title":"Remission to Normoalbuminuria during Multifactorial Treatment Preserves Kidney Function in Patients with Type 2 Diabetes and Microalbuminuria","volume":"19","author":"Gaede","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","article-title":"Trajectories of Kidney Function in Diabetes: A Clinicopathological Update","volume":"17","author":"Oshima","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a Target for Renoprotection in Patients with Type 2 Diabetic Nephropathy: Lessons from RENAAL","volume":"65","author":"Remuzzi","year":"2004","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdiacomp.2012.10.010","article-title":"Swedish National Diabetes Register Ongoing Treatment with Renin-Angiotensin-Aldosterone-Blocking Agents Does Not Predict Normoalbuminuric Renal Impairment in a General Type 2 Diabetes Population","volume":"27","author":"Afghahi","year":"2013","journal-title":"J. Diabetes Complicat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/HJH.0b013e3283495cd6","article-title":"Clinical Significance of Nonalbuminuric Renal Impairment in Type 2 Diabetes","volume":"29","author":"Penno","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.3346\/jkms.2009.24.S1.S75","article-title":"The Clinical Characteristics of Normoalbuminuric Renal Insufficiency in Korean Type 2 Diabetic Patients: A Possible Early Stage Renal Complication","volume":"24","author":"An","year":"2009","journal-title":"J. Korean Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.2337\/dc07-0387","article-title":"Clinical and Laboratory Profile of Patients with Type 2 Diabetes with Low Glomerular Filtration Rate and Normoalbuminuria","volume":"30","author":"Kramer","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00592-014-0650-7","article-title":"Updating the Natural History of Diabetic Nephropathy","volume":"51","author":"Pugliese","year":"2014","journal-title":"Acta Diabetol."},{"key":"ref_17","unstructured":"Terjung, R. (2011). Comprehensive Physiology, Wiley."},{"key":"ref_18","first-page":"1","article-title":"Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets","volume":"2015","author":"Atta","year":"2015","journal-title":"J. Diabetes Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1038\/sj.ki.5002386","article-title":"The Role of Protein Kinase C Activation in Diabetic Nephropathy","volume":"72","author":"Noh","year":"2007","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4239\/wjd.v5.i4.431","article-title":"Inflammation in Diabetic Kidney Disease","volume":"5","year":"2014","journal-title":"World J. Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and Molecular Cell Biology of Diabetic Complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Di Mauro, S., Scamporrino, A., Filippello, A., Di Marco, M., Di Martino, M.T., Scionti, F., Di Pino, A., Scicali, R., Malaguarnera, R., and Purrello, F. (2022). Mitochondrial RNAs as Potential Biomarkers of Functional Impairment in Diabetic Kidney Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158198"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic Classification of Diabetic Nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_24","first-page":"43","article-title":"Measurement of Glomerular Basement Membrane Thickness and Its Application to the Diagnosis of Thin-Membrane Nephropathy","volume":"116","author":"Dische","year":"1992","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI111523","article-title":"Structural-Functional Relationships in Diabetic Nephropathy","volume":"74","author":"Mauer","year":"1984","journal-title":"J. Clin. Investig."},{"key":"ref_26","first-page":"33","article-title":"So-Called Intercapillary Glomerulosclerosis: A Lesion Associated with Diabetes Mellitus. Morphogenesis and Significance","volume":"32","author":"Allen","year":"1941","journal-title":"Arch. Path"},{"key":"ref_27","first-page":"83","article-title":"Intercapillary Lesions in the Glomeruli of the Kidney","volume":"12","author":"Kimmelstiel","year":"1936","journal-title":"Am. J. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2337\/db08-0061","article-title":"From Fibrosis to Sclerosis: Mechanisms of Glomerulosclerosis in Diabetic Nephropathy","volume":"57","author":"Qian","year":"2008","journal-title":"Diabetes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2337\/dc18-1320","article-title":"Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score\u2013Matched Analysis of a Nationwide, Biopsy-Based Cohort Study","volume":"42","author":"Yamanouchi","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2337\/dc12-2572","article-title":"Renal Structure in Normoalbuminuric and Albuminuric Patients with Type 2 Diabetes and Impaired Renal Function","volume":"36","author":"Ekinci","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2337\/diabetes.49.3.476","article-title":"Course of Renal Function in Type 2 Diabetic Patients with Abnormalities of Albumin Excretion Rate","volume":"49","author":"Nosadini","year":"2000","journal-title":"Diabetes"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000448081","article-title":"Insights into the Mechanisms of the Acute Kidney Injury-to-Chronic Kidney Disease Continuum","volume":"134","author":"Takaori","year":"2016","journal-title":"Nephron"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rolland, A.-L., Garnier, A.-S., Meunier, K., Drablier, G., and Briet, M. (2021). Drug-Induced Acute Kidney Injury: A Study from the French Medical Administrative and the French National Pharmacovigilance Databases Using Capture-Recapture Method. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020168"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"903970","DOI":"10.3389\/fendo.2022.903970","article-title":"Recent Advances in Molecular Mechanisms of Acute Kidney Injury in Patients with Diabetes Mellitus","volume":"13","author":"Infante","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1681\/ASN.2015010006","article-title":"Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression","volume":"26","author":"Venkatachalam","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.12703\/r\/11-21","article-title":"AKI-to-CKD Transition Is a Potential Mechanism for Non-Albuminuric Diabetic Kidney Disease","volume":"11","author":"Lee","year":"2022","journal-title":"Fac. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S2213-8587(15)00094-7","article-title":"ERA-EDTA diabesity working group Non-Proteinuric Pathways in Loss of Renal Function in Patients with Type 2 Diabetes","volume":"3","author":"Porrini","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Di Marco, M., Urbano, F., Filippello, A., Di Mauro, S., Scamporrino, A., Miano, N., Coppolino, G., L\u2019Episcopo, G., Leggio, S., and Scicali, R. (2022). Increased Platelet Reactivity and Proinflammatory Profile Are Associated with Intima-Media Thickness and Arterial Stiffness in Prediabetes. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102870"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/archinte.167.22.2490","article-title":"Association of Kidney Function and Albuminuria with Cardiovascular Mortality in Older vs Younger Individuals: The HUNT II Study","volume":"167","author":"Hallan","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1479164113500798","article-title":"Albuminuria and Renal Function as Predictors of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes: A Nationwide Observational Study from the Swedish National Diabetes Register","volume":"10","author":"Svensson","year":"2013","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jdiacomp.2018.03.012","article-title":"Albuminuric and Non-Albuminuric Chronic Kidney Disease in Type 1 Diabetes: Association with Major Vascular Outcomes Risk and All-Cause Mortality","volume":"32","author":"Garofolo","year":"2018","journal-title":"J. Diabetes Complicat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00125-010-1854-1","article-title":"Estimated Glomerular Filtration Rate and Albuminuria Are Independent Predictors of Cardiovascular Events and Death in Type 2 Diabetes Mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Drury","year":"2011","journal-title":"Diabetologia"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"For the Renal Insufficiency and Cardiovascular Events (RIACE) Study Group, Penno, G., Solini, A., Orsi, E., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F., and Lamacchia, O. (2018). Non-Albuminuric Renal Impairment Is a Strong Predictor of Mortality in Individuals with Type 2 Diabetes: The Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicentre Study. Diabetologia, 61, 2277\u20132289.","DOI":"10.1007\/s00125-018-4691-2"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2337\/dc19-2049","article-title":"JDDM Study Group the Prognosis of Patients with Type 2 Diabetes and Nonalbuminuric Diabetic Kidney Disease Is Not Always Poor: Implication of the Effects of Coexisting Macrovascular Complications (JDDM 54)","volume":"43","author":"Yokoyama","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.ajkd.2021.11.011","article-title":"Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings from the Hong Kong Diabetes Biobank","volume":"80","author":"Jin","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1681\/ASN.2005121288","article-title":"Microalbuminuria and Risk for Cardiovascular Disease: Analysis of Potential Mechanisms","volume":"17","author":"Stehouwer","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_48","first-page":"827","article-title":"Increased Thickness of the Carotid Artery in Patients with Essential Hypertension and Microalbuminuria","volume":"9","author":"Bigazzi","year":"1995","journal-title":"J. Hum. Hypertens."},{"key":"ref_49","first-page":"S29","article-title":"Analogous Pathobiologic Mechanisms in Glomerulosclerosis and Atherosclerosis","volume":"31","author":"Diamond","year":"1991","journal-title":"Kidney Int. Suppl."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/j.ajkd.2018.02.364","article-title":"Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People with Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study","volume":"72","author":"Koye","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2337\/dc19-1438","article-title":"Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes","volume":"43","author":"Buyadaa","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO Clinical Practice Guideline for Lipid Management in CKD: Summary of Recommendation Statements and Clinical Approach to the Patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","article-title":"The UK Prospective Diabetes Study (UKPDS): Clinical and Therapeutic Implications for Type 2 Diabetes: Therapeutic Implications of the UKPDS","volume":"48","author":"King","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0272-6386(12)80696-2","article-title":"Long-Term Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Patients with Nephrotic Proteinuria","volume":"20","author":"Praga","year":"1992","journal-title":"Am. J. Kidney Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7326\/0003-4819-118-2-199301150-00009","article-title":"Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis","volume":"118","author":"Kasiske","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1523-1755.2003.00885.x","article-title":"The Risk of Developing End-Stage Renal Disease in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study","volume":"63","author":"Keane","year":"2003","journal-title":"Kidney Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"Khunti","year":"2022","journal-title":"Kidney Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients with Diabetic Nephropathy: A Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and Heart Failure Outcomes by Kidney Function\/Albuminuria in Chronic Kidney Disease and Diabetes","volume":"10","author":"Filippatos","year":"2022","journal-title":"JACC Heart Fail"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"967317","DOI":"10.3389\/fphar.2022.967317","article-title":"Network Meta-Analysis of Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"For the VADT Study Group, Agrawal, L., Azad, N., Bahn, G.D., Ge, L., Reaven, P.D., Hayward, R.A., Reda, D.J., and Emanuele, N.V. (2018). Long-Term Follow-up of Intensive Glycaemic Control on Renal Outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia, 61, 295\u2013299.","DOI":"10.1007\/s00125-017-4473-2"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients with Type 2 Diabetes and Renal Dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ki.2014.236","article-title":"The Potential for Renoprotection with Incretin-Based Drugs","volume":"86","author":"Tanaka","year":"2014","journal-title":"Kidney Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","article-title":"Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-Analysis","volume":"55","author":"Sarafidis","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1479164114542802","article-title":"The Effects of GLP-1 Analogues, DPP-4 Inhibitors and SGLT2 Inhibitors on the Renal System","volume":"11","author":"Schernthaner","year":"2014","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2147\/IJGM.S285191","article-title":"Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations","volume":"13","author":"Elnaem","year":"2020","journal-title":"Int. J. Gen. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e008531","DOI":"10.1136\/bmjopen-2015-008531","article-title":"Metformin Initiation and Renal Impairment: A Cohort Study in Denmark and the UK","volume":"5","author":"Christiansen","year":"2015","journal-title":"BMJ Open"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000471917","article-title":"Metformin-Associated Lactic Acidosis Undergoing Renal Replacement Therapy in Intensive Care Units: A Five-Million Population-Based Study in the North-West of Italy","volume":"44","author":"Mariano","year":"2017","journal-title":"Blood Purif."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Bell, S., Farran, B., McGurnaghan, S., McCrimmon, R.J., Leese, G.P., Petrie, J.R., McKeigue, P., Sattar, N., Wild, S., and McKnight, J. (2017). Risk of Acute Kidney Injury and Survival in Patients Treated with Metformin: An Observational Cohort Study. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0579-5"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"20420188211020664","DOI":"10.1177\/20420188211020664","article-title":"Diabetic Kidney Disease: Update on Clinical Management and Non-Glycaemic Effects of Newer Medications for Type 2 Diabetes","volume":"12","author":"Azmi","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and Renal Outcomes in Type 2 Diabetes: An Exploratory Analysis of the REWIND Randomised, Placebo-Controlled Trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus Insulin Glargine in Patients with Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7): A Multicentre, Open-Label, Randomised Trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"522-P","DOI":"10.2337\/db18-522-P","article-title":"Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)","volume":"67","author":"Bethel","year":"2018","journal-title":"Diabetes"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Leoncini, G., Russo, E., Bussalino, E., Barnini, C., Viazzi, F., and Pontremoli, R. (2021). SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094441"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and Safety of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 2 Diabetes Mellitus: Systematic Review and Network Meta-Analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e926086","DOI":"10.12659\/MSM.926086","article-title":"Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients","volume":"26","author":"Ohashi","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10741-020-10024-2","article-title":"Renal Protection: A Leading Mechanism for Cardiovascular Benefit in Patients Treated with SGLT2 Inhibitors","volume":"26","author":"Margonato","year":"2021","journal-title":"Heart Fail Rev."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Tsai, K.-F., Chen, Y.-L., Chiou, T.T.-Y., Chu, T.-H., Li, L.-C., Ng, H.-Y., Lee, W.-C., and Lee, C.-T. (2021). Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants, 10.","DOI":"10.3390\/antiox10081166"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 Inhibitors for the Prevention of Kidney Failure in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of Dapagliflozin on Development and Progression of Kidney Disease in Patients with Type 2 Diabetes: An Analysis from the DECLARE-TIMI 58 Randomised Trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes: Results from the CANVAS Program Randomised Clinical Trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mcna.2012.10.006","article-title":"Nonproteinuric Diabetic Nephropathy: When Diabetics Don\u2019t Read the Textbook","volume":"97","author":"Dwyer","year":"2013","journal-title":"Med. Clin. N. Am."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of Hyperglycaemia in Type 2 Diabetes, 2015: A Patient-Centred Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfy407","article-title":"SGLT-2 Inhibitors and GLP-1 Receptor Agonists for Nephroprotection and Cardioprotection in Patients with Diabetes Mellitus and Chronic Kidney Disease. A Consensus Statement by the EURECA-m and the DIABESITY Working Groups of the ERA-EDTA","volume":"34","author":"Sarafidis","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"109146","DOI":"10.1016\/j.diabres.2021.109146","article-title":"Comparison of Effects of SGLT-2 Inhibitors and GLP-1 Receptor Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients with\/without Albuminuria: A Systematic Review and Network Meta-Analysis","volume":"183","author":"Kawai","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., and Mayne, K.J. (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/5\/752\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:23:52Z","timestamp":1760124232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/5\/752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":102,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["biom13050752"],"URL":"https:\/\/doi.org\/10.3390\/biom13050752","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]}}}